GenBio AI Welcomes Emma Lundberg as Co-Founder and Chief Scientific Advisor
In this role, Lundberg will focus on the development of GenBio AI's data strategy and other scientific initiatives, advancing its mission to build a generative digital organism.
"I'm thrilled to join GenBio AI in building the next generation of biology through AI," said Lundberg. "The opportunity to train multi-scale and multi-modal computational models, at a much larger scale than what can be done in academia, to simulate life at the cellular level is a dream for any scientist, and a crucial step toward transforming biomedical research."
Lundberg is a globally recognized expert at the intersection of spatial proteomics, bioimaging, and artificial intelligence. She brings a remarkable track record of scientific innovation and cross-disciplinary leadership, most notably as Associate Professor of Bioengineering and Pathology at Stanford University and Professor at KTH Royal Institute of Technology in Sweden.
She also serves as Director of the Cell Atlas of the Human Protein Atlas project, an ambitious international effort to map the spatial organization of the human proteome. Her laboratory's pioneering research into protein localization and dynamics is foundational for constructing high-resolution virtual cell models and enabling in silico experimentation.
"Emma's visionary work in understanding cellular architecture through AI and imaging has redefined the boundaries of biomedical research," said Eric Xing, Co-founder and Chief Scientist, GenBio AI. "Her leadership will be instrumental as we push forward to develop the first virtual cell and virtual tissue using AI foundation models, toward our ultimate vision of an AI-driven digital organism that helps to phase out wet lab and animal testing."
"Her passion for science, collaborative spirit, entrepreneurial mindset, and bold ideas make her an incredible addition to our founding team," said Le Song, Chief Technology Officer, GenBio AI.
Lundberg's scientific excellence has been recognized globally, with honors including the Royal Microscopy Society's Scientific Achievement Award, the Göran Gustafsson Prize, and repeated recognition as one of the top 10 under 40 future leaders in biopharma and omics.
Beyond her academic achievements, Lundberg is known for championing open science and public engagement. She has introduced groundbreaking initiatives such as gamifying scientific discovery through citizen science and advising global research organizations, including the Human Proteome Organization, Human Cell Atlas, UniProt, and the Chan Zuckerberg Initiative's AI Virtual Cell project.
This official appointment marks a pivotal moment in shaping the company's scientific vision and future trajectory.
With Lundberg's deep expertise, entrepreneurial spirit, and bold ideas, GenBio AI is poised to accelerate its efforts in constructing an AI digital organism that will redefine the future of biomedicine.
About GenBio AIGenBio AI is building the world's first AI-driven Digital Organism (AIDO)—a set of multiscale foundation models to simulate, predict, and program biology at all levels. With offices in Palo Alto, Abu Dhabi, and Paris, GenBio AI is accelerating breakthroughs in drug design and biomedical research. Founded by top scientists from Carnegie Mellon University, Stanford University, the Mohamed bin Zayed University of Artificial Intelligence, and the Weizmann Institute of Science, and backed by leading investors, GenBio AI is redefining the future of life sciences.
View original content to download multimedia:https://www.prnewswire.com/news-releases/genbio-ai-welcomes-emma-lundberg-as-co-founder-and-chief-scientific-advisor-302483814.html
SOURCE GenBio AI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
24 minutes ago
- Forbes
Rethinking Work With AI: What Stanford's Groundbreaking Workforce Study Means For Healthcare's Future
AI systems should reduce cognitive load, clarify ambiguity, and work alongside teams as intelligent collaborators, not as black-box disruptors. What if the AI systems you're building solve the wrong problems and alienate the workforce you're trying to support? That's the uncomfortable reality laid bare by a new research study from Stanford University. While AI pilots race ahead across administrative and clinical functions, most are still built on a flawed assumption: that automating tasks equals progress. But for the people doing the work—clinicians, care coordinators, billing specialists—that's not what they asked for. The report, Future of Work with AI Agents, offers the most granular audit yet of how worker sentiment, task complexity, and technical feasibility collide in the age of artificial intelligence. Over 1,500 U.S. workers were surveyed across 104 occupations, producing the most detailed dataset yet on where AI could, and should, fit. Their preferences were paired with ratings from 52 AI experts to create a map of the true automation and augmentation landscape. For healthcare, the findings could not come at a more urgent moment. The healthcare sector faces a burned-out workforce, escalating administrative waste, and widespread dissatisfaction with digital tools that were meant to help. A majority of physicians report that documentation burden is a leading cause of burnout, with recent studies showing U.S. physicians spend excessive time on documentation tasks. Nurse attrition has also remained a concern since the pandemic. Meanwhile, AI adoption is surging, with the vast majority of health systems piloting or planning AI integration. However, there remains a lack of consistent frameworks to align these technologies with real-world clinical and operational dynamics. The result? Misplaced investment, fractured trust, and resistance from the very people AI is meant to assist. The Stanford study confirms it: the majority of tasks that healthcare workers want automated—like documentation, claims rework, or prior auth form generation—are not where AI tools are being focused. In fact, less than 2% of those high-desire tasks are showing up in actual LLM usage today. Instead, attention and venture funding are often diverted toward automating interpersonal communication, appeals, or triage. These are areas where trust, nuance, and empathy matter most. This is more than a technical oversight. It's a strategic miscalculation. This study clarifies that the future of AI in healthcare isn't about replacing human judgment—it's about protecting it. Leaders must pivot from automation-at-any-cost to augmentation-by-design. That means building AI systems that reduce cognitive load, clarify ambiguity, and work alongside teams as intelligent collaborators, not as black-box disruptors. And, most critically, it means listening to the workforce before you deploy. A New Lens on Work: Automation Desire vs. Technical Feasibility Stanford's framework introduces two powerful filters for every task: what workers want automated and what AI can do. This produces a four-quadrant map: This approach is especially revealing in healthcare, where: Critically, 69% of workers said their top reason for wanting AI was to free up time for higher-value work. Only 12% wanted AI to fully take over a task. The takeaway? Augmentation, not replacement. Green Light (Automate Now): R&D Opportunity (Invest in Next-Gen AI): Red Light (Approach with Caution): Y Combinator is one of the world's most influential startup accelerators, known for launching and funding early-stage technology companies, including many that shape the future of artificial intelligence. Its relevance in this context comes from its outsized role in setting trends and priorities for the tech industry: the types of problems YC-backed startups pursue often signal where talent, investment, and innovation are headed. The Stanford study highlights a striking disconnect between these startup priorities and actual workforce needs. Specifically, it found that 41% of Y Combinator-backed AI startups are developing solutions for tasks that workers have little interest in automating—referred to as 'Red Light Zones' or low-priority areas. This reveals a substantial missed opportunity: if leading accelerators like Y Combinator better aligned their focus with the real needs and preferences of the workforce, AI innovation could deliver far greater value and acceptance in the workplace. The Human Agency Scale: AI as a Teammate To move beyond binary thinking (automate vs. don't), the Stanford research team introduces a more nuanced framework: the Human Agency Scale (HAS). This five-tier model offers a conceptual scaffold for evaluating how AI agents should integrate into human workflows. Rather than asking whether a task should be automated, the HAS asks to what extent the human remains in control, how decision-making is shared, and what level of oversight is required. The scale ranges from H1 to H5, as follows: The Stanford study reveals a clear pattern across occupations: the majority of workers—particularly in healthcare—prefer H2 or H3. Specifically, 45.2% of tasks analyzed across all industries favor an H3 arrangement, in which AI acts as a collaborative peer. In healthcare contexts—where judgment, empathy, and contextual nuance are foundational—H3 is even more critical. In roles such as care coordination, utilization review, and social work, tasks often require a mix of real-time decision-making, human empathy, and risk stratification. A system built for full automation (H5) in these contexts would not only be resisted—it would likely produce unsafe or ethically problematic outcomes. Instead, what's required are AI agents that can surface relevant information, adapt to the evolving contours of a task, and remain responsive to human steering. John Halamka, President of Mayo Clinic Platform, reinforced this collaborative mindset in February 2025: 'We have to use AI,' he said, noting that ambient listening tools represent 'the thing that will solve many business problems' with relatively low risk. He cited Mayo's inpatient ambient nursing solutions, which handle '100% of the nursing charting without the nurse having to touch a keyboard,' but was clear that these tools are 'all augmenting human behavior and not replacing the human.' These insights echo a broader workforce trend: automation without agency is unlikely to succeed. Clinical leaders don't want AI to dictate care pathways or handle nuanced appeals independently. They want AI that reduces friction, illuminates blind spots, and extends their cognitive reach, without erasing professional identity or judgment. As such, designing for HAS Level 3 (equal partnership) is emerging as the gold standard for intelligent systems in healthcare. This model balances speed and efficiency with explainability and oversight. It also offers a governance and performance evaluation framework that prioritizes human trust. Building AI for HAS Level 3 requires features that go beyond prediction accuracy. Systems must be architected with: Healthcare doesn't need one-size-fits-all automation. It requires collaboration at scale, grounded in transparency and guided by human expertise. These perspectives align perfectly with the Stanford findings: workers don't fear AI—they fear being sidelined by it. The solution isn't to slow down AI development. It's to direct it with clarity, co-design it with the people who rely on it, and evaluate it not just by outputs but also by the experience and empowerment it delivers to human professionals. The true ROI of AI is trust, relief, and time reclaimed. Outcomes like 'claims processed' or 'notes generated' aren't enough. Metrics should track cognitive load reduced, time returned to patient care, and worker trust in AI recommendations. While throughput remains a necessary benchmark, these human-centered outcomes provide the clearest signal of whether AI improves the healthcare experience. Measurement frameworks must be longitudinal, capturing not just initial productivity but long-term operational resilience, clinician satisfaction, and sustainable value. Only then can we ensure that AI fulfills its promise to elevate both performance and purpose in healthcare. Dr. Rohit Chandra, Chief Digital Officer at Cleveland Clinic, gave voice to this idea in June 2025: 'It's made their jobs a ton easier. Patient interactions are a lot better because now patients actually engage with the doctor,' he said, referring to 4,000 physicians now using AI scribes. 'I'm hoping that we can keep building on the success that we've had so far to literally drive the documentation burden to zero.' Build With, Not For This moment is too important for misalignment. The Stanford study offers a blueprint. For healthcare leaders, the message is clear: If you want AI to scale, build with the workforce in mind. Prioritize the Green Light Zones. Invest in agentic systems that enhance, not override. Govern AI like a trusted partner, not a productivity engine. The future of AI in healthcare won't be determined by the size of your model. It will be defined by the quality of your teaming.
Yahoo
an hour ago
- Yahoo
Technetium-99m Market Size to Reach USD 6.29 Billion by 2031, Growing at a CAGR of 3.9%
NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial growth with the surging prevalence of chronic diseases and advancements in nuclear imaging techniques. The technetium-99m market is expected to reach US$6.29 billion by 2031 from US$ 4.61 billion in 2024; it is anticipated to register a CAGR of 3.9% during the forecast period. Technetium-99m (Tc-99m) is an extensively used radioactive isotope for diagnostic imaging in nuclear medicine. It holds the position of being the most common medical radioisotope worldwide and is used for over 40,000 imaging procedures daily in the US. To explore the valuable insights in the Technetium-99m Market report, you can easily download a sample PDF of the report - Some of the reasons behind Tc-99m's medical popularity are its ideal imaging properties, such as a short half-life of about six hours, suitable gamma energy, as well as providing a low radiation dose, giving it the capability to image organs such as the brain, heart, bones, lungs, kidneys, thyroid, and liver. The development of this market is sustained by increasing demand for Tc-99m-based radiopharmaceuticals in cardiovascular imaging and cancer detection, along with other clinical applications. North America stands as a huge market due to the advanced healthcare infrastructure and high rate of chronic diseases. Asia Pacific is growing fast owing to healthcare infrastructure investments and a focus on advanced diagnostics. The report carries an in-depth analysis of market trends, key players, and future opportunities. The technetium-99m market study focuses on an array of technologies that are expected to fuel the demand in the coming years. For Detailed Technetium-99m Market Insights, Visit: Overview of Report Findings Increasing Chronic Diseases Prevalence: The increase in prevalence of chronic diseases is a much stronger driver for the global Technetium-99m (Tc-99m) market. Tc-99m is the most important radioisotope used in more than 80% of nuclear medicine procedures in the world, mostly used in SPECT scanning for the diagnosis of cancer, cardiovascular diseases, and neurological disorders. According to the International Agency for Research on Cancer, the prevalence of cancer is high worldwide. It is estimated that there were 19.3 million cancer cases globally in 2020, and the number is expected to reach ~30.2 million by 2040. With an increase in the incidence of chronic diseases due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for higher diagnostic imaging techniques rises correspondingly. Such a scenario is evident in Asia Pacific, where chronic diseases such as diabetes and cardiovascular diseases are rising. Health care providers are thus increasingly adopting technetium-based imaging techniques for early diagnosis and for planning of treatment. This rise in demand is favoring the development of the Tc-99m market. Soaring Technological Advancements: Technological discoveries open a whole new set of vistas for the Technetium-99m (Tc-99m) market by making nuclear imaging more efficient, accurate, and accessible. At the forefront of these discoveries are radiopharmaceutical production technologies that include cyclotron-based Tc-99m production that nullifies the need for assessing the aged nuclear reactors and thereby assures more stable Tc-99m supplies. In addition, imaging instrument improvement, mainly within SPECT and hybrid imaging equipment such as SPECT/CT, have increased the resolution and diagnostic ability, thereby increasing Tc-99m's clinical utility. Further, automation in radiopharmacy and simultaneous integration of digital imaging workflows minimize human errors and maximize safety and efficiency. Artificial intelligence and machine learning are further being explored and used for image analysis to provide enhanced and more rapid diagnostic capabilities. Thus, these technological advancements account for the expanding sphere of clinical applications of Tc-99m while reducing operational costs in nuclear medicine, which include its accessibility to emerging markets. Several innovations and various avenues for research, investment, and patient care are being formed in the Tc-99m market. Stay Updated on The Latest Technetium-99m Market Trends: Geographical Insights: In 2024, North America led the technetium-99m market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Market Segmentation By application, the market is categorized into cardiovascular, bone scan, respiratory, tumor imaging, and others. The bone scan segment accounted for the largest share of the market in 2024. Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest share of the market in 2024. The technetium-99m market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Lantheus Medical Imaging Inc., Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc., Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, and SHINE Technologies LLC are major companies operating in the market. Trending Topics: Emergence of Hybrid Imaging Techniques, Advancements in Radiopharmaceutical Development, and Sustainability and Cost-Effectiveness Initiatives. Purchase Premium Copy of Global Technetium-99m Market Size and Growth Report (2021-2031) at: Global Headlines on Technetium-99m Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScan (Kit for the Preparation of Technetium Tc 99m Succimer Injection). BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone. IAEA Launches Research Project to Develop New Technetium-99m Radiopharmaceuticals. Conclusion The demand for technetium-99m is expanding at a rapid pace with increasing requirements for advanced diagnostic imaging, primarily for areas such as oncology, cardiology, and neurology. The largest market for Technetium-99m is North America followed by the easy availability of radiopharmaceuticals and higher average cost of kit for Tc-99m. The technetium-99m market in Asia Pacific is segmented into Japan, China, and India and is also expected to grow at the fastest CAGR due to the increasing investments in improving healthcare infrastructure and rising focus on advanced diagnostics. The development of imaging, such as SPECT and hybrid SPECT/CT systems, is becoming more accurate and reliable in Tc-99m using diagnostics. Furthermore, ongoing development of production technologies, such as non-reactor-based ones address Mo-99 supply chain issues, the progenitor isotope for Tc-99m. Thus, continuous advancements in imaging instruments and manufacturing technologies and government initiatives for bettering nuclear medication facilities are expected to drive the market during the forecast period. The report from The Insight Partners lists several stakeholders—including radiopharmaceutical manufacturers, medical equipment suppliers, healthcare providers, and regulatory bodies—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. For More Latest Life Sciences Research Reports & Industry Analysis - Trending Related Reports: Bone Scan Market Growth, Top Key Players, and Regional Forecast by 2031 Respiratory Disposable Devices Market Size, Trends, Shares, and Forecast – 2031 Respiratory Medical Device Market Size, Trends, Shares, and Forecast – 2031 Respiratory Drug Delivery Devices Market Size, Trends, Shares, and Forecast - 2031 The Tumor Embolization Market Size is expected to register a CAGR of 8.9% from 2025 to 2031 The Heart Tumor Market Size is expected to register a CAGR of 8.0% from 2025 to 2031 The Tumor Ablation Market Size is expected to register a CAGR of 12.5% from 2025 to 2031 The Respiratory Protection Equipment Market Size is expected to register a CAGR of 6.8% from 2025 to 2031 Respiratory Medical Device Professional Market Size Drivers, Opportunities, Trends, and Forecasts by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release - Logo - View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Healthcare Dispensing Systems Market worth $6.27 billion by 2030 with 6.3% CAGR
DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Healthcare Dispensing Systems Market, valued at US$4.36 billion in 2024, stood at US$4.61 billion in 2025 and is projected to advance at a resilient CAGR of 6.3% from 2025 to 2030, culminating in a forecasted valuation of US$6.27 billion by the end of the period. The market's accelerated growth trajectory is primarily driven by increasing demand for precision dispensing in pharmaceutical manufacturing, diagnostics, and medical device production. As the industry moves toward automation and miniaturization, advanced dispensing systems are streamlining workflows, improving dosing accuracy, and reducing contamination risks. Key trends such as the rise of lab-on-chip devices, personalized medicine, and point-of-care testing are expanding adoption across end-user segments. Additionally, technological innovations in microfluidics, robotics, and sensor integration are enhancing system performance. Regulatory support for digital health infrastructure and growing investment in life sciences R&D is further accelerating market expansion. Download PDF Brochure: Browse in-depth TOC on "Healthcare Dispensing Systems Market" 400 - Tables50 - Figures400 - Pages By type, the market is divided into automatic dispensing systems, semi-automated dispensing systems, stand-alone/manual dispensing instruments, and OEM/dispensing components. Automatic dispensing systems accounted for the largest share of the healthcare dispensing systems market in 2024. Their dominance is attributed to the increasing demand for high-throughput, precise, and contamination-free dispensing in diagnostic labs, pharmaceutical production, and medical device assembly. These systems are widely adopted due to their integration capabilities with automated workflows, improved operational efficiency, and reduced error rates. Advancements in tipless and non-contact dispensing, real-time data feedback, and motion control have further enhanced their appeal. Growing R&D activities, rising diagnostic volumes, and a global push for lab automation are expected to sustain the segment's leadership during the forecast period. By end user, the healthcare dispensing systems market is segmented into healthcare providers, pharma & biotech companies, MedTech companies, and other end users based on the end user. Among these, healthcare providers represent the largest segment, driven by the widespread use of dispensing systems across hospitals, diagnostic labs, outpatient centers, pharmacies, and long-term care facilities. These systems support accurate and safe medication administration, fluid handling in diagnostic workflows, and real-time inventory management. Hospitals and labs require automated dispensing to meet high patient volumes and ensure safety and quality standards compliance. The growing demand for efficient resource utilization, staff workload reduction, and integrated data systems further accelerates adoption among healthcare providers. For instance, over 90% of US acute care hospitals use Automated Dispensing Cabinets (ADCs), saving up to 35 hours of labor weekly and $64,300 annually, highlighting the strong impact of automation on hospital efficiency, cost reduction, and patient safety. As care delivery models shift toward decentralized and patient-centric approaches, healthcare providers continue to invest in dispensing systems to support scalable, connected, and efficient operations. By geography, in 2024, North America held the largest market share for healthcare dispensing systems. This dominance is due to a well-established diagnostic infrastructure, advanced pharmaceutical manufacturing capabilities, and a high concentration of biotech and medtech firms. The region benefits from substantial R&D investments, early adoption of automation, and strong support from both the government and private sector for digital transformation in healthcare. Additionally, the increasing demand for decentralized testing, the presence of major dispensing technology providers, and an emphasis on quality and regulatory compliance have all contributed to market leadership. The integration of smart dispensing solutions in diagnostics and medical device production further supports continued growth. Request Sample Pages : The prominent healthcare dispensing systems market players include Nordson Corporation (US), DH Life Sciences, LLC (US), and BRAND GMBH+Co. KG (Germany), Fisnar (US), PARKER HANNIFIN CORP (US), BioDot (US), Thermo Fisher Scientific Inc. (US), bdtronic (Germany), Agilent Technologies, Inc. (US), Hamilton Company (US), Graco Inc. (US), Imagene Technology Inc (US), Harro Höfliger Verpackungsmaschinen GmbH (Germany), Tecan Trading AG (Switzerland), IVEK Corporation (US), Revvity, Inc. (US), QIAGEN (Germany), Gilson Incorporated (US), Ascential Technologies (US), and LGC?Biosearch Technologies (UK). Nordson Corporation (US): Nordson Corporation is a key healthcare dispensing systems sector leader, leveraging its robust engineering expertise and extensive product portfolio to maintain a dominant market position. The company's global manufacturing footprint and enduring partnerships with pharmaceutical, biotech, and medical device companies reinforce its strategic advantage. Nordson delivers diverse precision dispensing solutions, specifically engineered for critical applications such as drug formulation, diagnostics production, and medical device assembly. The integration of automation, rigorous quality control measures, and strict compliance adherence into its systems solidifies its reputation as a preferred collaborator within regulated healthcare environments. Significant investment in research and development enables Nordson to continuously innovate, optimizing system precision, throughput speed, and reliability. Operating in over 35 countries across North America, Europe, Asia, and Latin America, the company provides localized support and expert technical services to its global clientele. Its deep-rooted experience in fluid management and microdispensing technologies cements Nordson's role as a pivotal enabler of high-throughput manufacturing processes within the healthcare industry. BioDot Inc. (US): BioDot Inc. is a pivotal entity in the healthcare dispensing systems sector. It is particularly recognized for its innovative ultra-low volume dispensing technologies for life sciences, diagnostics, and high-throughput manufacturing arenas. The company's expertise lies in precision fluid deposition systems, essential for applications such as point-of-care diagnostics, lateral flow assays, and biosensor development. BioDot's portfolio includes advanced solutions like the BioJet and the newly launched MODULIS platform. These systems are characterized by their integration of modular automation, intelligent conveyance mechanisms, and robust vision systems, facilitating scalable and high-volume production processes. With a footprint extending across over 50 countries, BioDot emphasizes system adaptability and manufacturing efficiency, enabling end-to-end dispensing solutions that empower manufacturers to expedite product development and shorten commercialization timelines. For more information, Inquire Now! Related Reports: Healthcare IT Market Drug Discovery Services Market Healthcare Analytics Market Healthcare IT Integration Market Microfluidics Market Get access to the latest updates on Healthcare Dispensing Systems IT Companies and Healthcare Dispensing Systems Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
